Recently, the internationally renowned publishing house WILEY has just announced its Top Cited Article 2020-2021 . Professor XIA Rong in Department of Blood Transfusion, Huashan Hospital received congratulations from WILEY for his team’s research paper.

The article Early Experience with Convalescent Plasma as Immunotherapy for COVID-19 in China: Knowns and Unknowns published in Vox Sanguinis, the leading journal of blood transfusion medicine, presented the preliminary analysis on the effectiveness and safety of convalescent plasma treatment in COVID-19 (CCP), and also proposed for a better design of randomized control group and other related studies in order to further evaluate CCP’s  effectiveness and potential adverse effects.

According to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9), issued by the National Health Commission on March 14th, 2022, CCP is involved in treatment of COVID patients in early course, especially for patients with high-risk factors, high viral load, and fast progress. The recommended transfusion dose is 200~500 mL (4~5mL/kg), and additional transfusion could be considered according to patient's individual condition and viral load.

Professor XIA Rong's team has been dedicated to basic clinical research on blood components and transfusion-related immune regulation for a long time. Their research achievements have been orally delivered at the 36th International Congress of ISBT, which gained peer recognition. CHEN Binzhen, a postgraduate student from the Department of Blood Transfusion, Huashan Hosptital, is the first author of the paper, and Professor XIA Rong is the corresponding author.

Source: Huashan Hospital, Fudan University

Tranlated by ZHOU Yanjun;

Reviewed by ZHU Shanshan, JIANG Nizhen.